Page last updated: 2024-11-05

thalidomide and Arsenic Encephalopathy

thalidomide has been researched along with Arsenic Encephalopathy in 2 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Imamura, T1
Ide, H1
Yasunaga, H1
Gibbels, E1

Other Studies

2 other studies available for thalidomide and Arsenic Encephalopathy

ArticleYear
History of public health crises in Japan.
    Journal of public health policy, 2007, Volume: 28, Issue:2

    Topics: Arsenic Poisoning; Arsenicals; Drug-Related Side Effects and Adverse Reactions; Environmental Pollut

2007
[Differential diagnosis of polyneuritides].
    Der Nervenarzt, 1969, Volume: 40, Issue:10

    Topics: Arsenic Poisoning; Carbon Disulfide; Diabetic Neuropathies; Diagnosis, Differential; Diphtheria; Hum

1969